SCHEMBL19985016

SCHEMBL19985016

Cc1ccc(NC(=O)C(NC(=O)C2=CCC(N)C=C2)c2ccccc2)c(Br)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
OGT O15294 1/20 0.43
ALDH1A1 P00352 5/20 0.39
LMNA P02545 2/20 0.39
MAPT P10636 7/20 0.39
GAA P10253 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
PKM P14618 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
TP53 P04637 1/20 0.39
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
POLB P06746 3/20 0.38
KDM4E B2RXH2 2/20 0.37
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17364129 0.78 NPC1 (0.50) NPC1RAB9ASMN1; SMN2OGTALDH1A1
SCHEMBL16098100 0.70 SMN1; SMN2 (0.62) NPC1RAB9ASMN1; SMN2OGTALDH1A1
SCHEMBL19985015 0.70 SMN1; SMN2 (0.62) NPC1RAB9ASMN1; SMN2OGTALDH1A1
SCHEMBL6718465 0.67 MEN1 (0.55) SMN1; SMN2ALDH1A1LMNAMAPTGAA
SCHEMBL6824801 0.64 BRD4 (0.60) RAB9ASMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL17378284 0.64 HPN (0.45) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL29175040 0.64 SMN1; SMN2 (0.66) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL1703978 0.63 RAB9A (0.68) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL12218189 0.62 RAB9A (1.00) NPC1RAB9ASMN1; SMN2ALDH1A1LMNA
SCHEMBL29386575 0.61 KMT2A (0.50) NPC1RAB9ASMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180079730-A1 ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES SHIFA BIOMEDICAL CORP (US) 2018-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180079730-A1 ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES PCSK9, PCSK7, PCSK6 NPC1 53/4885RAB9A 2189/4885SMN1; SMN2 4600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.